Lexicon Pharmaceuticals, Inc. (LXRX)
Largest Insider Buys in Sector
LXRX Stock Price History Chart
LXRX Stock Performance
About Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and …
Insider Activity of Lexicon Pharmaceuticals, Inc.
Over the last 12 months, insiders at Lexicon Pharmaceuticals, Inc. have bought $0 and sold $0 worth of Lexicon Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Lexicon Pharmaceuticals, Inc. have bought $65.15M and sold $158,440 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 90,000 shares for transaction amount of $94,797 was made by COATS LONNEL (Chief Executive Officer) on 2023‑11‑16.
List of Insider Buy and Sell Transactions, Lexicon Pharmaceuticals, Inc.
| 2023-11-16 | Chief Executive Officer | 90,000 0.0365% | $1.05 | $94,797 | +62.26% | |||
| 2023-11-10 | Chief Executive Officer | 10,000 0.0041% | $1.01 | $10,100 | +69.37% | |||
| 2023-10-12 | director | 148,820 0.0604% | $1.03 | $153,805 | +62.50% | |||
| 2023-10-11 | director | 342,874 0.1415% | $1.08 | $370,784 | +57.94% | |||
| 2023-10-10 | director | 508,306 0.2365% | $1.14 | $579,367 | +50.45% | |||
| 2023-09-14 | President and CFO | 10,000 0.0042% | $1.38 | $13,800 | +24.63% | |||
| 2023-08-04 | VP, Human Resources | 6,000 0.0024% | $1.84 | $11,040 | -9.89% | |||
| 2023-06-29 | Chief Executive Officer | 10,000 0.0053% | $2.16 | $21,600 | -21.43% | |||
| 2023-06-26 | Chief Executive Officer | 10,000 0.0053% | $2.18 | $21,792 | -21.20% | |||
| 2023-06-23 | Chief Executive Officer | 10,000 0.0056% | $2.50 | $24,950 | -27.85% | |||
| 2023-06-23 | VP, Human Resources | 10,000 0.0054% | $2.43 | $24,300 | -27.85% | |||
| 2023-06-22 | Chief Executive Officer | 40,000 0.0211% | $2.31 | $92,400 | -26.08% | |||
| 2023-06-20 | President and CFO | 12,000 0.0063% | $2.33 | $28,000 | -27.12% | |||
| 2023-06-05 | 27.78M 15.0418% | $2.60 | $72.22M | -32.28% | ||||
| 2022-08-05 | 2.43M 1.2253% | $2.50 | $6.07M | -18.02% | ||||
| 2022-08-05 | 147,390 0.0744% | $2.50 | $368,475 | -18.02% | ||||
| 2022-08-01 | 16.17M 9.7545% | $2.50 | $40.43M | -2.11% | ||||
| 2022-08-01 | 1.97M 1.1852% | $2.50 | $4.91M | -2.11% | ||||
| 2021-03-15 | Sale | VP, Finance & Accounting | 22,912 0.0161% | $6.92 | $158,440 | -35.08% | ||
| 2020-12-16 | 10.94M 9.4404% | $3.20 | $35M | +59.57% |
Insider Historical Profitability
| Ulys, LLC | 10 percent owner | 135327888 37.4359% | $0.78 | 4 | 0 | <0.0001% |
| Artal International S.C.A. | 78634381 21.7527% | $0.78 | 4 | 0 | +10.29% | |
| Invus Advisors, L.L.C. | 50859331 14.0693% | $0.78 | 2 | 0 | <0.0001% | |
| Invus Public Equities, L.P. | 32259461 8.924% | $0.78 | 27 | 0 | <0.0001% | |
| Invus C.V. | 30248505 8.3677% | $0.78 | 3 | 0 | +21.63% |
Institutional Investor Ownership
| Artal Group S A | $282.13M | 32.52 | 117.55M | 0% | +$0 | 1.23 | |
| Fidelity Investments | $33.35M | 3.84 | 13.89M | +510.33% | +$27.88M | <0.01 | |
| BlackRock | $18.46M | 2.13 | 7.69M | +9.82% | +$1.65M | <0.0001 | |
| The Vanguard Group | $15.36M | 1.77 | 6.4M | +7.04% | +$1.01M | <0.0001 | |
| OrbiMed | $8.5M | 0.98 | 3.54M | New | +$8.5M | 0.07 |